ALFACON 1 INDUCTION COMPARED TO STANDARD THERAPY IN HEPATITIS C VIRUS

ALFACON 1 诱导与丙型肝炎病毒标准治疗的比较

• 批准号: 6307324
• 负责人: PAUL J POCKROS
• 金额: $ 2.74万
• 依托单位: SCRIPPS RESEARCH INSTITUTE, THE
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6307324
• 关键词: clinical research; hepatitis C; hepatitis C virus; human subject; human therapy evaluation; immunotherapy; interferon inducers; interferons; microorganism disease chemotherapy

This is a multi-center, randomized, open-labeled, parallel group trial to determine the efficacy and tolerability of four doses of interfeorn Alfacon 1 induction treatment regimens in comparison to standard regimen interferon therapy for patients with chronic hepatitis C virus infection. Endpoint of evaluation of efficacy will be normalization of ALT and disappearance of detectable HCV RNA from serum.

这是一项多中心、随机、开放标签、平行组试验，旨在确定4种剂量的Alfarorn Alfacon 1诱导治疗方案与标准方案干扰素治疗慢性丙型肝炎病毒感染患者的疗效和耐受性。疗效评价终点为ALT正常化和血清中可检测到的HCV RNA消失。